drugset / Trial / NCT00733642
Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
Parallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponezumab | Monoclonal antibody | 1 mg/kg | Other |
| Subject | Ponezumab | Monoclonal antibody | 3 mg/kg | Other |
| Subject | Ponezumab | Monoclonal antibody | 5 mg/kg | Other |
| Subject | Ponezumab | Monoclonal antibody | 10 mg/kg | Other |